Myriad Asset Management Advisors LLC Purchases Shares of 38,512 Novo Nordisk A/S $NVO

Key Points

• Myriad Asset Management Advisors purchased 38,512 Novo Nordisk shares in the second quarter, worth approximately $1.85 million. Institutional investors and hedge funds own 11.54% of the company.
• Novo Nordisk faces mixed market sentiment: demand for GLP-1 weight-loss drugs remains strong and its Awiqli insulin recently launched in the U.S., but analysts cited flat Wegovy sales, pricing pressure, pipeline setbacks and competition from Eli Lilly.
• Analyst opinion is largely cautious, with 15 Hold ratings, four Buys and one Sell; the stock has an average rating of Hold and a consensus price target of $64.94, compared with a recent price of $46.52.

Myriad Asset Management Advisors LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,512 shares of the company's stock, valued at approximately $1,846,000.

Several other large investors have also recently made changes to their positions in the stock. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $25,000. Scarborough Advisors LLC purchased a new stake in Novo Nordisk A/S in the first quarter valued at approximately $26,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after purchasing an additional 260 shares in the last quarter. Jackson Grant Investment Advisers Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth $29,000. Finally, Quaker Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 186.0% during the fourth quarter. Quaker Wealth Management LLC now owns 615 shares of the company's stock worth $31,000 after buying an additional 400 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk CEO Mike Doustdar said demand for weight-loss medicines still has a “long runway,” arguing that GLP-1 adoption remains in its early stages and could ultimately reduce healthcare costs and improve productivity. Novo Nordisk CEO sees long runway for weight-loss drugs
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, expanding the company’s diabetes portfolio and providing a potential new commercial growth driver beyond obesity treatments. Awiqli now available in the US
• Positive Sentiment: Erste Group raised its 2026 earnings-per-share estimate for Novo Nordisk to $3.27 from $3.20, while bullish commentary argues that the company’s broader cardiometabolic pipeline is being undervalued. Analysts raise Novo Nordisk earnings estimates
• Neutral Sentiment: Novo Nordisk is suing Eli Lilly over weight-loss-drug advertising. Management says the lawsuit is intended to ensure fair competition, but the dispute also highlights the intensifying rivalry between the two leading obesity-drug companies. Novo Nordisk CEO defends lawsuit against Eli Lilly
• Negative Sentiment: Analysts cited flat Wegovy sales, pricing challenges, pipeline setbacks and the risk that Eli Lilly is pulling ahead in the oral obesity market. These concerns, combined with the Berenberg downgrade, are weighing on sentiment toward NVO. Berenberg cuts Novo Nordisk as Lilly takes the oral market

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Zacks Research cut Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Monday, July 13th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a report on Wednesday. Weiss Ratings raised Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. Finally, Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Four analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $64.94.

Novo Nordisk A/S Trading Down 1.4%

NYSE:NVO opened at $46.52 on Thursday. The firm has a market cap of $207.71 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76. The stock has a fifty day moving average price of $47.24 and a 200 day moving average price of $44.61. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th will be given a dividend of $0.5786 per share. The ex-dividend date of this dividend is Monday, August 17th. This represents a dividend yield of 254.0%. Novo Nordisk A/S's payout ratio is currently 42.79%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source